A study by Weill Cornell Medicine researchers has found that interferon-alpha can help patients with myeloproliferative neoplasms, a type of blood cancer. The drug works by forcing mutant blood stem cells to transform into short-lived white blood cells. This process is key because it reduces the pool of harmful mutant cells, which are the primary drivers of the disease. The broad activity of interferon-alpha, however, can lead to significant side effects, showing the need for more focused therapeutic strategies based on these mechanistic insights.
Myeloproliferative neoplasms occur when DNA mutations in blood stem cells cause an overproduction of certain blood cell types, such as megakaryocytes, which produce platelets. Interferon-alpha helps reduce these imbalances and deplete the pool of mutant cells. This imbalance can lead to serious complications, including an raised risk of heart attack and stroke due to excessive platelet production. By targeting mutant cells, interferon-alpha not only alleviates symptoms but also addresses the root cause of the disease.
Unraveling Interferon-Alpha’s Effects
Published in Nature Genetics, the study used single-cell profiling to investigate how interferon-alpha works. Led by Dr. Anna Nam, the team analyzed gene activity, surface proteins, and other characteristics of blood cells from patients with essential thrombocythemia, a myeloproliferative neoplasm. Dr. Nam, an assistant professor of pathology and laboratory medicine, emphasized that these findings provide strategies for managing not only myeloproliferative neoplasms but potentially other blood cancers as well. The study’s advanced profiling methods, developed at Weill Cornell Medicine, allowed the team to examine thousands of individual blood cells, providing an unprecedented level of detail into the drug’s effects.
They compared blood cells before and after interferon-alpha treatment, examining how mutant and non-mutant cells responded differently. The researchers found that interferon-alpha triggers an emergency infection response, prompting blood stem cells to rapidly mature into neutrophils, a type of white blood cell with a short lifespan. This process, known as inflammaging, depletes blood stem cells over time, with mutant cells more susceptible. The study also revealed that interferon-alpha induces blood stem cells to produce lymphoid cells, helping balance lymphoid and myeloid cell populations. Additionally, interferon-alpha was found to suppress inflammaging-related gene programs, further contributing to its therapeutic benefits.
Balancing Blood Cell Populations
These findings offer new insights into interferon-alpha’s mechanisms, suggesting potential for more selective and effective treatments for myeloproliferative neoplasms and other blood cancers. Dr. Nam’s lab is also investigating whether natural interferon-alpha may contribute to autoimmune conditions through its inflammatory response. Understanding this dual role of interferon-alpha could lead to better management of both cancer and autoimmune disorders.
The study’s co-first authors were Chhiring Lama, a research assistant, and Dr. Danielle Isakov, who completed the PhD portion of her MD/PhD program in the Nam Laboratory, with Dr. Nam as the senior author. Their work provides a foundation for developing targeted therapies that could improve outcomes for patients with blood cancers and potentially precancerous conditions. Furthermore, the study highlights how type 1 interferon perturbates clonal competition by reshaping human blood development, offering a deeper understanding of its role in hematopoiesis and disease.
Leave a Reply